期刊
ACS INFECTIOUS DISEASES
卷 8, 期 5, 页码 1031-1040出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.2c00001
关键词
bovine leukemia virus; glycoprotein 51; mutant bacteriophage Q beta; vaccine
资金
- National Institutes of Health [R01AI146210]
- Michigan State University
In this study, a peptide conjugate was constructed using a specific peptide epitope and a mutant bacteriophage carrier, successfully developing a vaccine candidate against bovine leukemia virus. The vaccine candidate generated durable immunity and effectively inhibited viral infection.
Bovine leukemia virus (BLV) is a C-type retrovirus of cattle that causes huge economic losses with high infection rates in the majority of countries worldwide. To develop an anti-BLV vaccine, we constructed a peptide conjugate using the envelope glycoprotein gp51-peptide epitope, a putative receptor-binding site. This highly antigenic peptide was covalently linked to a mutant bacteriophage carrier (mQ beta) using two different linker strategies, isothiocyanate (NCS) and dinitrophenyl adipate. Both constructs elicited higher anti-BLV peptide IgG titers than the corresponding conjugate with keyhole limpet hemocyanin protein carrier (gold standard) in mice with the NCS linker strategy requiring less sample processing. The mQ beta -gp51-peptide construct is the first BLV peptide-based vaccine candidate to generate durable immunity (>539 days), which recognized both native gp51 protein and BLV particles and significantly decreased fusion of a susceptible cell line exposed to infectious BLV. These results support the high translational and animal health potential of the vaccine construct.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据